AQ
Aquestive Therapeutics, Inc.
AQST · NASDAQ
$4.78 +3.02% (+$0.14)
1M -0.42%
Market Cap $599.7M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$4.49
6.1% downside
Current Price
$4.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AQST is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 11.09x
EV/FFO N/A
P/E N/A
Growth
9 /100
Declining Rev. growth 2.24%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 97.52%
Gross margin 67.04%
FCF margin 84.95%
Quality
7 /100
Poor Asset turnover 0.41x
ROIC 45.30%
ROA 59.22%
Debt
43 /100
Moderate Int. coverage -3.79x
Current ratio 7.19x
Debt/Assets N/A
Stability
27 /100
Unstable EPS volatility 192.79%
Beta 1.47x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AQST
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Daniel Barber
Employees
147
Headquarters
Warren
Upcoming events
04 NOV
Earnings
Upcoming earnings report